Activation of ERK/IER3/PP2A-B56γ-positive feedback loop in lung adenocarcinoma by allelic deletion of B56γ gene.
暂无分享,去创建一个
Isao Matsumoto | Hirofumi Takemura | Tomoko Ito | S. Ozaki | H. Sakurai | H. Takemura | Hiroshi Sakurai | T. Oyama | Rachanee Chanasong | Satoru Ozaki | Ei Kawahara | Takeru Oyama | Tomoko Ito | Rachanee Chanasong | Yuki Mizutani | E. Kawahara | I. Matsumoto | Yuki Mizutani
[1] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[2] C. Marshall,et al. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation , 1995, Cell.
[3] Yigong Shi. Serine/Threonine Phosphatases: Mechanism through Structure , 2009, Cell.
[4] A. Arlt,et al. Role of the immediate early response 3 (IER3) gene in cellular stress response, inflammation and tumorigenesis. , 2011, European journal of cell biology.
[5] J. Minna,et al. Alterations of the PPP2R1B gene in human lung and colon cancer. , 1998, Science.
[6] F. Porteu,et al. IEX‐1: a new ERK substrate involved in both ERK survival activity and ERK activation , 2002, The EMBO journal.
[7] S. Artan,et al. Detection of deletions and/or amplifications of genes related with lung cancer by multiplex ligation-dependent probe amplification (MLPA) technique , 2009, Cancer biology & therapy.
[8] A. Vincent-Salomon,et al. Loss of heterozygosity at 13q13 and 14q32 predicts BRCA2 inactivation in luminal breast carcinomas , 2013, International journal of cancer.
[9] Wu Mx. Roles of the stress-induced gene IEX-1 in regulation of cell death and oncogenesis. , 2003 .
[10] R. Tomasini,et al. IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation. , 2014, The Journal of clinical investigation.
[11] V. Band,et al. The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants# , 2009, Oncogene.
[12] M. Jung,et al. Identification and characterization of a radiation-inducible glycosylated human early-response gene. , 1996, Cancer research.
[13] Yoo Jin Jung,et al. The transcriptional landscape and mutational profile of lung adenocarcinoma , 2012, Genome research.
[14] C. van Hoof,et al. PP2A: the expected tumor suppressor. , 2005, Current opinion in genetics & development.
[15] W. Hahn,et al. Multiple pathways regulated by the tumor suppressor PP2A in transformation. , 2008, Trends in molecular medicine.
[16] Chung-Liang Ho,et al. Allelic loss of 14q32 in the pathogenesis of gastrointestinal and ampullary malignancies: mapping of the target region to a 17 cM interval , 2005, Journal of Cancer Research and Clinical Oncology.
[17] Takashi Takahashi,et al. Loss of heterozygosity (LOH) at 17q and 14q in human lung cancers , 1998, Oncogene.
[18] Mei X. Wu,et al. Clinical Significance of IEX-1 Expression in Ovarian Carcinoma , 2011, Ultrastructural pathology.
[19] M. Zorzetto,et al. EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells , 2013, Journal of Cancer Research and Clinical Oncology.
[20] D. Ribatti,et al. Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma , 2009, Clinical Cancer Research.
[21] A. Zentella,et al. Protein phosphatase 2A is essential to maintain active Wnt signaling and its Aβ tumor suppressor subunit is not expressed in colon cancer cells , 2015, Molecular carcinogenesis.
[22] Shaohua Chen,et al. Expression and distribution of PPP2R5C gene in leukemia , 2011, Journal of hematology & oncology.
[23] M. Lung,et al. Genetic alterations detected on chromosomes 13 and 14 in Chinese non-small cell lung carcinomas. , 2003, Cancer letters.
[24] Mei X. Wu,et al. Immediate early response gene X-1, a potential prognostic biomarker in cancers , 2013, Expert opinion on therapeutic targets.
[25] J. Keats,et al. Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes. , 2009, Cancer research.
[26] Y. Tesfaigzi,et al. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? , 2009, Cell cycle.
[27] V. Janssens,et al. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. , 2001, The Biochemical journal.
[28] M. Isobe,et al. Loss of heterozygosity of 14q32 in colorectal carcinoma. , 1999, Cancer genetics and cytogenetics.
[29] A. Al-Hakim,et al. Metastatic recurrence of early-stage colorectal cancer is linked to loss of heterozygosity on chromosomes 4 and 14q , 2006, Journal of Clinical Pathology.
[30] P. Cohen,et al. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. , 1992, The Biochemical journal.
[31] M. Isobe,et al. Allelic imbalance of 14q32 in esophageal carcinoma. , 2002, Cancer genetics and cytogenetics.
[32] Y. Kaneko,et al. Deletion mapping of 14q32 in human neuroblastoma defines an 1,100-kb region of common allelic loss. , 2000, Medical and pediatric oncology.
[33] K. Azuma,et al. Prognostic Significance of the Immediate Early Response Gene X-1 (IEX-1) Expression in Pancreatic Cancer , 2008, Annals of Surgical Oncology.
[34] J. Hecht,et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] J. Minna,et al. Progress in understanding the molecular pathogenesis of human lung cancer. , 1998, Biochimica et biophysica acta.
[36] F. Porteu,et al. B56‐containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX‐1 and ERK , 2006, The EMBO journal.
[37] C. Croce,et al. Loss of heterozygosity at chromosome 11q in lung adenocarcinoma: identification of three independent regions. , 1995, Cancer research.
[38] Cheng-Wei Wu,et al. The B56γ3 Regulatory Subunit of Protein Phosphatase 2A (PP2A) Regulates S Phase-specific Nuclear Accumulation of PP2A and the G1 to S Transition* , 2010, The Journal of Biological Chemistry.
[39] Rony Seger,et al. The ERK Cascade: Distinct Functions within Various Subcellular Organelles. , 2011, Genes & cancer.
[40] J. Settleman,et al. Targeting the RAF-MEK-ERK pathway in cancer therapy. , 2009, Cancer letters.
[41] R. Trojanec,et al. Non-small cell lung cancer--genetic predictors. , 2013, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.
[42] T. Shioda,et al. Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression. , 2006, Cancer research.
[43] L. Lau,et al. Genomic structure, cDNA sequence, and expression of gly96, a growth factor-inducible immediate-early gene encoding a short-lived glycosylated protein. , 1993, Oncogene.
[44] R. Bernards,et al. Protein phosphatase 2A regulatory subunits and cancer. , 2009, Biochimica et biophysica acta.
[45] Y. Ishikawa,et al. Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations. , 2010, Lung cancer.
[46] P. Validire,et al. Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features. , 2005, Lung cancer.
[47] Xuan Liu,et al. B56γ Tumor-Associated Mutations Provide New Mechanisms for B56γ-PP2A Tumor Suppressor Activity , 2013, Molecular Cancer Research.
[48] H Nojima,et al. A truncated isoform of the PP2A B56 subunit promotes cell motility through paxillin phosphorylation , 2000, The EMBO journal.
[49] H. Sakurai,et al. Dynamic Regulation of Extracellular Signal-Regulated Kinase (ERK) by Protein Phosphatase 2A Regulatory Subunit B56γ1 in Nuclei Induces Cell Migration , 2013, PloS one.